Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·Galvanize Therapeutics

Galvanize Therapeutics raises $130M Series D to widen sales of its Aliya ablation system

HealthQuest Capital led the round for the Redwood City company, whose pulsed electric field system is 510(k)-cleared for surgical ablation of soft tissue. Galvanize says more than 4,000 procedures have been performed with it.

From a company announcement published Nov. 16, 2026, and FDA 510(k) records retrieved through openFDA
A Galvanize Therapeutics generator with needle accessories, in an image the company published with its announcement of the first commercial Aliya EX procedures.
A Galvanize Therapeutics generator with needle accessories, in an image the company published with its announcement of the first commercial Aliya EX procedures.Courtesy of Galvanize Therapeutics
Amount
$130M
Type
Series D
Company
Galvanize Therapeutics
Lead investor
HealthQuest Capital
Sector
Medtech
Announced
Nov. 16, 2026

Galvanize Therapeutics already has a product on the U.S. market. Now it has $130 million to sell more of it. The Redwood City, Calif., company said Nov. 16 that it closed an oversubscribed Series D to expand sales of its Aliya pulsed electric field system and fund the next products behind it.

HealthQuest Capital, which makes growth equity investments in health care companies that already have products on the market, led the round. Olympus Innovation Ventures and Braidwell joined as new investors. Existing backers Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company and T. Rowe Price Associates also took part. Galvanize did not disclose a valuation or its total funding to date.

Why it matters: This is a growth round for a device that is already cleared and selling, with Fidelity Management & Research Company and T. Rowe Price Associates among the returning investors. Galvanize said physicians have now performed more than 4,000 procedures with Aliya.

What the system does

Aliya delivers short bursts of high-voltage electrical energy to ablate soft tissue during surgery without relying on heat, according to the company. The FDA cleared the original Aliya System through the 510(k) pathway in June 2022, and cleared the next-generation Aliya EX System in May 2026, according to the agency's database. The company said the system is not commercially available outside the U.S.

Galvanize, which is pursuing uses in oncology and chronic lung disease, said early data suggest the energy may prompt the release of antigens that could activate the immune system. It added that the effectiveness of Aliya for producing an immune response that benefits patients has not been established, and that the system is not intended to treat any specific disease.

The company said its PROPEL registry has enrolled more than 300 patients, and that more than 40 peer-reviewed publications have explored the technology.

Where the money goes

Proceeds will pay for commercial expansion of Aliya, more clinical evidence, development of RheOx, an investigational therapy for chronic bronchitis, and next-generation pulsed electric field products, the company said. Garheng Kong, HealthQuest's founder and managing partner, will join the Galvanize board.

"This financing marks an important inflection point for Galvanize," said Doug Godshall, the company's chairman and chief executive.

Kong said HealthQuest had "followed Galvanize's progress closely over the years" before investing. HealthQuest manages about $2 billion in committed capital, according to the release.

What to watch

Norwest, one of the returning investors, also co-led Nanopath's $25 million Series B on Nov. 10. For Galvanize, the measures to watch are procedure growth beyond 4,000, enrollment in the PROPEL registry and progress on RheOx, which remains limited to investigational use in the U.S.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.